Friday saw EF Hutton maintain a positive outlook on Trevi Therapeutics (NASDAQ:TRVI) shares, reiterating a Buy rating with a steady price target of $21.00. The optimism stems from the progress of Trevi's clinical trials, particularly the Phase 2b CORAL trial, which is investigating treatments for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The trial has reached a significant milestone, enrolling half of its intended participants.
The ongoing study is set to undergo a sample size re-estimation (SSRE) after the participants complete six weeks of treatment. The results of this re-estimation are anticipated in December 2024 and could lead to three potential outcomes: maintaining the current sample size, increasing it, or assessing the trial for futility. The final topline results of the CORAL trial are expected in the first half of 2025.
Another study, the HAP trial, has finished dosing, and results are also expected by December 2024. Additionally, the Phase 2a RIVER trial for renal cell carcinoma (RCC) is on track, with topline results projected in early 2025.
EF Hutton's analysis of Trevi's prospects includes modeling for Haduvio, the company's product aimed at suppressing coughs associated with IPF and refractory chronic cough (RCC). The firm applies a 70% probability of success (POS) for IPF treatments and a 50% POS for chronic cough. Their financial model incorporates a 30% discount rate and the possibility of additional capital raises affecting the final share count.
The valuation method used by EF Hutton involves a combination of Free Cash Flow to the firm (FCFF), discounted EPS (dEPS), and sum-of-the-parts (SOP) models. These models are equal-weighted, averaged, and rounded to the nearest whole number, which supports their 12-month price target for Trevi Therapeutics.
In other recent news, Trevi Therapeutics has reported significant advancements in its clinical trials. The company's Phase 2b CORAL trial, aimed at treating chronic cough in idiopathic pulmonary fibrosis patients, has reached 50% of its enrollment target.
Moreover, Trevi has completed dosing in its Human Abuse Potential study, with topline results expected in December 2024. The Phase 2a RIVER trial, which focuses on refractory chronic cough treatment, has reached its planned sample size, with topline results expected in the first quarter of 2025.
Analyst firms Raymond James, H.C. Wainwright, and EF Hutton have initiated coverage on Trevi Therapeutics. Raymond James and H.C. Wainwright have assigned an Outperform and Buy rating respectively, while EF Hutton has given a Buy rating.
Despite a reported net loss of $12.4 million in its Second Quarter 2024 Earnings Conference Call, Trevi Therapeutics, with funding secured until 2026, continues to advance several trials. These recent developments present an overview of the company's progress in its ongoing trials and analyst coverage.
InvestingPro Insights
Trevi Therapeutics' financial health and market performance offer additional context to the positive outlook from EF Hutton. According to InvestingPro data, the company's market capitalization stands at $219.23 million, reflecting its current market valuation. Despite the optimistic clinical trial progress, InvestingPro Tips highlight that Trevi is not profitable over the last twelve months and net income is expected to drop this year. This aligns with the company's focus on research and development, typical for biopharmaceutical firms in the clinical trial phase.
The stock has shown significant volatility, with a 125.37% year-to-date price total return, indicating strong investor interest in Trevi's potential. However, an InvestingPro Tip notes that the stock has taken a big hit over the last week, with a 1-week price total return of -9.31%. This recent dip could present an opportunity for investors who share EF Hutton's bullish outlook.
Importantly, Trevi holds more cash than debt on its balance sheet, which is crucial for funding ongoing clinical trials. This financial stability is further supported by the fact that liquid assets exceed short-term obligations, providing a buffer for the company's operations as it progresses through its clinical pipeline.
For readers interested in a deeper dive into Trevi Therapeutics' financials and market performance, InvestingPro offers 8 additional tips and a comprehensive set of real-time metrics to inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.